All In MedTech

Device Trial Radar · NCT05582018

Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

Pilot Study to Assess the Safety and Effectiveness of the Use of BioTraceIO 360 for PSM and Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Sep 5, 2023

Primary completion

Apr 15, 2024

Study completion May 15, 2024

Sponsor

Lead sponsor
Techsomed Medical Technologies LTDNot on our public-company list
Sponsor type
Industry
First posted
Oct 17, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures Multi-center (up to 5 investigational sites) prospective single-arm clinical investigation. Sample size - 30 subjects.

Conditions

  • Hepatocellular Carcinoma
  • Metastatic Liver Cancer

Interventions

  • BioTraceIO 360Device

    Use of the device for planning, monitoring and assessment of liver tissue ablations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EffectivenessTime frame: 1 year
  2. SafetyTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Einstein Medical Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.